Attention: Restrictions on use of AUA, AUAER, and UCF content in third party applications, including artificial intelligence technologies, such as large language models and generative AI.
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence technologies and infrastructure, including deep learning, machine learning and large language models and generative AI.

Incontinence after Prostate Treatment: AUA/GURS/SUFU Guideline

Using AUA Guidelines

This AUA guideline is provided free of use to the general public for academic and research purposes. However, any person or company accessing AUA guidelines for promotional or commercial use must obtain a licensed copy. To obtain the licensable copy of this guideline, please contact Keith Price at kprice@auanet.org.

Published 2019; Amended 2024

Unabridged version of this guideline [pdf]
Guideline Amendment Summary [pdf]
Evaluation Algorithm [pdf]
Surgical Management Algorithm [pdf]
Sling Failure Algorithm [pdf]
AUS Failure Algorithm [pdf]

To cite this guideline:

Breyer BN, Kim SK, Kirkby E, Marianes A, Vanni AJ, Westney OL. Updates to Incontinence After Prostate Treatment: AUA/GURS/SUFU Guideline (2024). J Urol. Published online July 27, 2024. doi:10.1097/JU.0000000000004088

Panel Members

Jaspreet S. Sandhu, MD; Benjamin N. Breyer, MD; Craig Comiter, MD; James A. Eastham, MD; Christopher Gomez, MD; Daniel J. Kirages, PT; Chris Kittle; Alvaro Lucioni, MD; Victor W. Nitti, MD; John T. Stoffel, MD; O. Lenaine Westney, MD; Kurt McCammon, MD

Amendment Panel

Benjamin N. Breyer, MD; Alex J. Vanni, MD; O. Lenaine Westney, MD

Staff and Consultants

Sennett K. Kim; Erin Kirkby, MS; Alexis Marianes, PhD; M. Hassan Murad, MD

SUMMARY

Purpose

This Guideline on incontinence after prostate treatment (IPT) is intended to facilitate care decisions and aid clinicians in the management of patients who have incontinence after undergoing treatment of localized prostate cancer and benign prostatic hyperplasia (BPH). The multiple treatments that exist for patients with IPT are discussed and evaluated herein.

Methodology

The systematic review utilized to inform this Guideline was conducted by a methodology team at the Mayo Clinic Evidence-Based Practice Research Program. The scope of the topic and the discussion of the final systematic review used to develop Guideline statements was conducted in conjunction with the Incontinence after Prostate Treatment Panel. A research librarian conducted searches in Ovid MEDLINE (from 2000 to December 21st, 2017), Cochrane Central Register of Controlled Trials (from 2000 to December 21st, 2017) and Cochrane Databases of Systematic Reviews (from 2000 to December 21st, 2017). Searches of electronic databases were supplemented by reviewing reference lists of relevant articles. Panel members identified additional references through 12/31/2018. In 2023, the Incontinence after Prostate Treatment Guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published Guidelines. The methodologist searched Embase (1996 to June 2023), EBM Reviews – Cochrane Central Register of Controlled Trials (May 2023), EBM Reviews – Cochrane database of Systematic Reviews (2005 to June 2023), Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily (2019 to June 2023).

GUIDELINE STATEMENTS

Pre-Treatment

  1. Clinicians should inform patients undergoing localized prostate cancer treatment of all known factors that could affect continence. (Moderate Recommendation; Evidence Level: Grade B)
  2. Clinicians should counsel patients regarding the risk of sexual arousal incontinence and climacturia following localized prostate cancer treatment. (Strong Recommendation; Evidence Level: Grade B)
  3. Clinicians should inform patients undergoing radical prostatectomy that incontinence is expected in the short-term and generally improves to near baseline by 12 months after surgery but may persist and require treatment. (Strong Recommendation; Evidence Level: Grade A)
  4. Prior to radical prostatectomy, clinicians may offer patients pelvic floor muscle exercises or pelvic floor muscle training. (Conditional Recommendation; Evidence Level: Grade C)
  5. Clinicians should inform patients undergoing radical prostatectomy or transurethral resection of the prostate after radiation therapy of the high rate of urinary incontinence following these procedures. (Moderate Recommendation; Evidence Level: Grade C)

Post-Prostate Treatment

  1. In patients who have undergone radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training in the immediate post-operative period. (Moderate Recommendation; Evidence Level: Grade B)
  2. In patients with bothersome stress urinary incontinence after prostate treatment, clinicians may offer surgery as early as six months if incontinence is not improving despite conservative therapy. (Conditional Recommendation; Evidence Level: Grade C)
  3. In patients with bothersome stress urinary incontinence after prostate treatment despite conservative therapy, clinicians should offer surgical treatment at one year post-prostate treatment. (Strong Recommendation; Evidence Level: Grade B)

Evaluation of Incontinence after Prostate Treatment

  1. Clinicians should evaluate patients with incontinence after prostate treatment with history, physical exam, and appropriate diagnostic modalities to categorize type and severity of incontinence and degree of bother. (Clinical Principle)
  2. In patients with urgency urinary incontinence or urgency predominant mixed urinary incontinence, clinicians should offer treatment options per the American Urological Association Overactive Bladder Guideline. (Clinical Principle)
  3. Prior to surgical intervention for stress urinary incontinence, clinicians should confirm stress urinary incontinence by history, physical exam, or ancillary testing. (Clinical Principle)
  4. Clinicians should inform patients with incontinence after prostate treatment of management options for their incontinence, including surgical and non-surgical options. (Clinical Principle)
  5. In patients with incontinence after prostate treatment, clinicians should discuss risk, benefits, and expectations of different treatments using the shared decision-making model. (Clinical Principle)
  6. Prior to surgical intervention for stress urinary incontinence, clinicians should perform cystourethroscopy to assess for urethral and bladder pathology that may affect outcomes of surgery. (Expert Opinion)
  7. Clinicians may perform urodynamic testing in patients prior to surgical intervention for stress urinary incontinence in cases where it may facilitate diagnosis or counseling. (Conditional Recommendation; Evidence Level: Grade C)

Treatment Options

  1. In patients seeking treatment for incontinence after radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training. (Moderate Recommendation; Evidence Level: Grade B)
  2. Clinicians should discuss the option of artificial urinary sphincter with patients who are experiencing mild to severe stress urinary incontinence after prostate treatment. (Strong Recommendation; Evidence Level: Grade B)
  3. Prior to implantation of artificial urinary sphincter, clinicians should ensure that patients have adequate physical and cognitive abilities to operate the device. (Clinical Principle)
  4. In patients who select artificial urinary sphincter, clinicians should preferentially utilize a single cuff perineal approach. (Moderate Recommendation; Evidence Level: Grade C)
  5. Clinicians should discuss the option of male slings with patients as treatment options for mild to moderate stress urinary incontinence after prostate treatment. (Moderate Recommendation; Evidence Level: Grade B)
  6. Clinicians should not routinely implant male slings in patients with severe stress incontinence. (Moderate Recommendation; Evidence Level: Grade C)
  7. Clinicians may offer adjustable balloon devices to non-radiated patients with mild to severe stress urinary incontinence after prostate treatment. (Conditional Recommendation; Evidence Level: Grade C)
  8. Clinicians should manage patients with stress urinary incontinence after treatment of benign prostatic hyperplasia the same as patients that have undergone radical prostatectomy. (Moderate Recommendation; Evidence Level: Grade C)
  9. In patients with stress urinary incontinence after primary, adjuvant, or salvage radiotherapy who are seeking surgical management, clinicians should offer artificial urinary sphincter over male slings or adjustable balloons. (Moderate Recommendation; Evidence Level: Grade C)
  10. In patients with incontinence after prostate treatment, clinicians should counsel patients that efficacy is low and cure is rare with urethral bulking agents. (Strong Recommendation; Evidence Level: Grade B)
  11. Clinicians should consider other potential treatments for incontinence after prostate treatment as investigational, and patients should be counseled accordingly. (Expert Opinion)

Complications after Surgery

  1. Clinicians may counsel patients regarding risk factors for artificial urinary sphincter erosion. (Conditional Recommendation; Evidence Level: Grade C)
  2. Clinicians should counsel patients that artificial urinary sphincter will likely lose effectiveness over time, and reoperations are common. (Strong Recommendation; Evidence Level: Grade B)
  3. In patients with persistent or recurrent urinary incontinence after artificial urinary sphincter or sling, clinicians should again perform history, physical examination, and/or other investigations to determine the cause of incontinence. (Clinical Principle)
  4. In patients with persistent or recurrent stress urinary incontinence after sling, clinicians should recommend an artificial urinary sphincter. (Moderate Recommendation; Evidence Level: Grade C)
  5. In patients with persistent or recurrent stress urinary incontinence after artificial urinary sphincter, clinicians should discuss artificial urinary sphincter revision with the patient. (Strong Recommendation; Evidence Level: Grade B)
  6. In patients presenting with infection or erosion of an artificial urinary sphincter or sling, clinicians should perform explantation and reimplantation should be delayed. (Clinical Principle)
  7. After explanting an eroded device, clinicians may manage artificial urinary sphincter urethral cuff erosion intra-operatively with urethral catheter alone, in situ urethroplasty, or anastomotic urethroplasty. (Expert Opinion)

Special Situations

  1. Clinicians should discuss urinary diversion with patients who are unable to obtain long-term quality of life due to incontinence after prostate treatment. (Expert Opinion)
  2. In patients with bothersome incontinence during sexual activity, clinicians should offer treatment. (Moderate Recommendation; Evidence Level: Grade C)
  3. In patients with stress urinary incontinence following urethral reconstructive surgery, clinicians may offer artificial urinary sphincter and counsel that complication rates are higher. (Conditional Recommendation; Evidence Level: Grade C)
  4. In patients with incontinence after prostate treatment and erectile dysfunction, clinicians may offer a concomitant or staged procedure. (Conditional Recommendation; Evidence Level: Grade C)
  5. In patients with symptomatic vesicourethral anastomotic stenosis or bladder neck contracture, clinicians should treat the patient prior to surgery for incontinence after prostate treatment. (Clinical Principle)

INTRODUCTION

Background

IPT causes emotional and financial distress to patients afflicted with this condition by delaying patients’ re-entry into society, inhibiting relationships, and carrying an economic burden for families and stakeholders. It is a condition that has gained visibility not only due to the extensive use of surgery for prostate cancer but also given the proliferation of men’s continence products available to the lay public. 

Given that IPT is caused by treatment of the prostate, it is by definition iatrogenic. As such, it is perhaps preventable or predictable. Understanding the nature of IPT is crucial for patients and clinicians during recovery and extended survivorship following prostate treatment. Clinicians benefit from being able to assess which patients will likely experience further symptom recovery versus those who will not. This allows clinicians to set clear and reasonable expectations regarding the short-, medium-, and long-term sequelae of IPT.

Although most clinicians are familiar with the more commonly known term “post-prostatectomy incontinence,” this Guideline uses the term “IPT”, as a more inclusive term that covers the management of patients who have incontinence after undergoing treatment of localized prostate cancer and BPH. Evaluation of the patient, risk factors for IPT which should be discussed with all patients prior to treatment, assessment of the patient prior to intervention, and a stepwise approach to management are covered in this Guideline. Possible maneuvers to decrease rates of IPT, with specific focus placed on patients with SUI, are also explored. The multiple treatments that exist for patients with IPT are discussed and evaluated, including physical therapy, medications, and surgery. Algorithms for patient evaluation, surgical management, and device failure are provided for practitioners. While no clear convention for severity grading is accepted, for the purposes of this Guideline the following definitions are being used based on patient reported pads per day usage. Patient reported outcome measures, standing cough test, and daily pad weights can also be employed. Social continence is considered one or fewer pads per day that is tolerable to the patient.1, 2 Mild, moderate, severe incontinence is considered 1-2, 2-4, 5 plus pads per day reported by the patient, respectively.3-5

Methodology

The systematic review utilized to inform this Guideline was conducted by a methodology team at Mayo Clinic Evidence-Based Practice Research Program. Determination of the Guideline scope and review of the final systematic review to inform Guideline statements was conducted in conjunction with the Incontinence after Prostate Treatment Panel. The update search performed in 2023 was conducted by an independent methodologist.

Panel Formation

The IPT Panel was created in 2017 by the American Urological Association Education and Research, Inc. (AUAER). This Guideline was developed in collaboration with the Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU). The Practice Guidelines Committee (PGC) of the American Urological Association (AUA) selected the Panel Chair, who in turn appointed additional panel members with specific expertise in this area, in conjunction with SUFU. Funding of the Panel was provided by the AUA with contributions from SUFU; panel members received no remuneration for their work.

In 2023, the Incontinence after Prostate Treatment Amendment Panel was created by the AUA to review new literature and provide updates herein.

Searches and Article Selection

A comprehensive search of several databases from 2000 to December 21st, 2017 was completed. Databases included Ovid MEDLINE Epub Ahead of Print, Ovid Medline In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. The search strategy was designed and conducted by an experienced medical reference librarian with input from the Guideline methodologist. Controlled vocabulary supplemented with keywords was used to search for studies on IPT. The search was restricted to studies published in English and available in full text in the peer reviewed literature.

In 2023, the Incontinence after Prostate Treatment Guideline was updated through the AUA amendment process in which newly published literature is reviewed and integrated into previously published Guidelines. The methodologist searched Embase (1996 to June 2023), EBM Reviews – Cochrane Central Register of Controlled Trials (May 2023), EBM Reviews – Cochrane database of Systematic Reviews (2005 to June 2023), Ovid MEDLINE(R) and Epub Ahead of Print, In-Process, In-Data-Review & Other Non-Indexed Citations and Daily (2019 to June 2023).

Data Abstractions

Two reviewers independently selected studies and extracted data using standardized, pilot tested forms created in a systematic review software management system (Distiller SR, Evidence Partners, Ottawa, Canada). Disagreements were resolved by discussion between the two reviewers. Two main types of data were abstracted: baseline characteristics (study design, objective, inclusion and exclusion criteria, sample size, age, body mass index [BMI], intervention, period of follow up), and outcome data (number of patients who were incontinent and those with incontinence improvement, mean pads per day, quality of life [QoL], and complications).

Risk of Bias Assessment

The Newcastle Ottawa scale, which evaluates cohort selection, comparability and outcomes assessment, was used for non-randomized controlled trials (RCTs). The Cochrane risk of bias tool which evaluates random sequence generation, allocation concealment, blinding, and attrition was used for evaluation of RCTs.

Data Synthesis

When meta-analysis was appropriate, methodologists utilized the random-effects model a priori because of the anticipated heterogeneity across study populations and settings. Otherwise, outcomes were evaluated using narrative and descriptive approaches.

Determination of Evidence Strength

The categorization of evidence strength is conceptually distinct from the quality of individual studies. Evidence strength refers to the body of evidence available for a particular question and includes individual study quality in addition to consideration of study design; consistency of findings across studies; adequacy of sample sizes; and generalizability of samples, settings, and treatments for the purposes of the Guideline. Investigators graded the strength of evidence for key comparisons and outcomes for each Key Question, using the approach described in the Agency for Healthcare Research and Quality Evidence-based Practice Center Methods Guide for Comparative Effectiveness and Effectiveness Reviews.6 Strength of evidence assessments were based on the following domains:

  • Study limitations, based on the overall risk of bias across studies (low, medium, or high)
  • Consistency of results across studies
  • Directness of the evidence linking the intervention and health outcomes
  • Precision of the estimate of effect, based on the number and size of studies and confidence intervals for the estimates (precise or imprecise)
  • Reporting bias, based on whether or not the studies defined and reported primary outcomes and whether or not we identified relevant unpublished studies (suspected or undetected)

The AUA employs a 3-tiered strength of evidence system to underpin evidence-based guideline statements. Table 1 summarizes the GRADE categories, definitions, and how these categories translate to the AUA strength of evidence categories. In short, high certainty by GRADE translates to AUA A-category strength of evidence, moderate to B, and both low and very low to C.

The AUA categorizes body of evidence strength as Grade A (well-conducted and highly-generalizable RCTs or exceptionally strong observational studies with consistent findings), Grade B (RCTs with some weaknesses of procedure or generalizability or moderately strong observational studies with consistent findings), or Grade C (RCTs with serious deficiencies of procedure or generalizability or extremely small sample sizes or observational studies that are inconsistent, have small sample sizes, or have other problems that potentially confound interpretation of data). By definition, Grade A evidence is evidence about which the Panel has a high level of certainty, Grade B evidence is evidence about which the Panel has a moderate level of certainty, and Grade C evidence is evidence about which the Panel has a low level of certainty.

TABLE 1: Strength of Evidence Definitions

AUA Nomenclature: Linking Statement Type to Evidence Strength

The AUA nomenclature system explicitly links statement type to body of evidence strength, level of certainty, magnitude of benefit or risk/burdens, and the Panel’s judgment regarding the balance between benefits and risks/burdens (Table 2). Strong Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is substantial. Moderate Recommendations are directive statements that an action should (benefits outweigh risks/burdens) or should not (risks/burdens outweigh benefits) be undertaken because net benefit or net harm is moderate. Conditional Recommendations are non-directive statements used when the evidence indicates that there is no apparent net benefit or harm or when the balance between benefits and risks/burden is unclear. All three statement types may be supported by any body of evidence strength grade. Body of evidence strength Grade A in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances, and that future research is unlikely to change confidence. Body of evidence strength Grade B in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances, but better evidence could change confidence. Body of evidence strength Grade C in support of a Strong or Moderate Recommendation indicates that the statement can be applied to most patients in most circumstances, but better evidence is likely to change confidence. Body of evidence strength Grade C is only rarely used in support of a Strong Recommendation. Conditional Recommendations also can be supported by any evidence strength. When body of evidence strength is Grade A, the statement indicates that benefits and risks/burdens appear balanced, the best action depends on patient circumstances, and future research is unlikely to change confidence. When body of evidence strength Grade B is used, benefits and risks/burdens appear balanced, the best action also depends on individual patient circumstances, and better evidence could change confidence. When body of evidence strength Grade C is used, there is uncertainty regarding the balance between benefits and risks/burdens, alternative strategies may be equally reasonable, and better evidence is likely to change confidence.

Where gaps in the evidence existed, the Panel provides guidance in the form of Clinical Principles or Expert Opinions with consensus achieved using a modified Delphi technique if differences of opinion emerged.7 A Clinical Principle is a statement about a component of clinical care that is widely agreed upon by urologists or other clinicians for which there may or may not be evidence in the medical literature. Expert Opinion refers to a statement, achieved by consensus of the Panel, that is based on members' clinical training, experience, knowledge, and judgment for which there is no evidence.

Table 2: AUA Nomenclature Linking Statement Type to Level of Certainty, Magnitude of Benefit or Risk/Burden, and Body of Evidence Strength

Peer Review and Document Approval

An integral part of the Guideline development process at the AUA is external peer review. The AUA conducted a thorough peer review process to ensure that the document was reviewed by experts in the treatment of IPT. In addition to reviewers from the AUA PGC, Science and Quality Council (SQC), and Board of Directors (BOD), the document was reviewed by representatives from AUA and SUFU as well as external content experts. Additionally, a call for reviewers was placed on the AUA website from January 14 to 28, 2019 to allow any additional interested parties to request a copy of the document for review. The Guideline was also sent to the Urology Care Foundation to open the document further to the patient perspective. The draft Guideline document was distributed to 49 external peer reviewers. All peer review comments were blinded and sent to the Panel for review. In total, 33 reviewers (9 AUA PGC, SQC, and BOD reviewers; 22 external reviewers; and 2 public reviewers) provided comments. At the end of the peer review process, a total of 476 comments were received. Following comment discussion, the Panel revised the draft as needed. Once finalized, the Guideline was submitted for approval to the AUA PGC, SQC and BOD as well as the governing bodies of SUFU for final approval.

In 2024, as a part of the amendment process, the AUA conducted a thorough peer review process. A call for peer reviewers was posted on February 7th, 2024 and the draft Guideline document was distributed to 85 peer reviewers, 32 of whom submitted comments. The Amendment Panel reviewed and discussed all submitted comments and revised the draft as needed. Once finalized, the Guideline was submitted to the AUA PGC, SQC, and BOD for final approval in addition to the approval bodies of collaborators SUFU and the Society of Genitourinary Reconstructive Surgeons (GURS).

GUIDELINE STATEMENTS

Pre-Treatment

Guideline Statement 1

Clinicians should inform patients undergoing localized prostate cancer treatment of all known factors that could affect continence. (Moderate Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 2

Clinicians should counsel patients regarding the risk of sexual arousal incontinence and climacturia following localized prostate cancer treatment. (Strong Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 3

Clinicians should inform patients undergoing radical prostatectomy that incontinence is expected in the short-term and generally improves to near baseline by 12 months after surgery but may persist and require treatment. (Strong Recommendation; Evidence Level: Grade A)

Discussion


Guideline Statement 4

Prior to radical prostatectomy, clinicians may offer patients pelvic floor muscle exercises or pelvic floor muscle training. (Conditional Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 5

Clinicians should inform patients undergoing radical prostatectomy or transurethral resection of the prostate after radiation therapy of the high rate of urinary incontinence following these procedures. (Moderate Recommendation; Evidence Level: Grade C)

Discussion


Post-Prostate Treatment

Guideline Statement 6

In patients who have undergone radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training in the immediate post-operative period. (Moderate Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 7

In patients with bothersome stress urinary incontinence after prostate treatment, clinicians may offer surgery as early as six months if incontinence is not improving despite conservative therapy. (Conditional Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 8

In patients with bothersome stress urinary incontinence after prostate treatment despite conservative therapy, clinicians should offer surgical treatment at one year post-prostate treatment. (Strong Recommendation; Evidence Level: Grade B)

Discussion


Evaluation of Incontinence After Prostate Treatment

Guideline Statement 9

Clinicians should evaluate patients with incontinence after prostate treatment with history, physical exam, and appropriate diagnostic modalities to categorize type and severity of incontinence and degree of bother. (Clinical Principle)

Discussion


Guideline Statement 10

In patients with urgency urinary incontinence or urgency predominant mixed urinary incontinence, clinicians should offer treatment options per the American Urological Association Overactive Bladder Guideline. (Clinical Principle)

Discussion


Guideline Statement 11

Prior to surgical intervention for stress urinary incontinence, clinicians should confirm stress urinary incontinence by history, physical exam, or ancillary testing. (Clinical Principle)

Discussion


Guideline Statement 12

Clinicians should inform patients with incontinence after prostate treatment of management options for their incontinence, including surgical and non-surgical options. (Clinical Principle)

Discussion


Guideline Statement 13

In patients with incontinence after prostate treatment, clinicians should discuss risk, benefits, and expectations of different treatments using the shared decision-making model. (Clinical Principle)

Discussion


Guideline Statement 14

Prior to surgical intervention for stress urinary incontinence, clinicians should perform cystourethroscopy to assess for urethral and bladder pathology that may affect outcomes of surgery. (Expert Opinion)

Discussion


Guideline Statement 15

Clinicians may perform urodynamic testing in patients prior to surgical intervention for stress urinary incontinence in cases where it may facilitate diagnosis or counseling. (Conditional Recommendation; Evidence Level: Grade C)

Discussion


Treatment Options

Guideline Statement 16

In patients seeking treatment for incontinence after radical prostatectomy, clinicians should offer pelvic floor muscle exercises or pelvic floor muscle training. (Moderate Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 17

Clinicians should discuss the option of artificial urinary sphincter with patients who are experiencing mild to severe stress urinary incontinence after prostate treatment. (Strong Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 18

Prior to implantation of artificial urinary sphincter, clinicians should ensure that patients have adequate physical and cognitive abilities to operate the device. (Clinical Principle)

Discussion


Guideline Statement 19

In patients who select artificial urinary sphincter, clinicians should preferentially utilize a single cuff perineal approach. (Moderate Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 20

Clinicians should discuss the option of male slings with patients as treatment options for mild to moderate stress urinary incontinence after prostate treatment. (Moderate Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 21

Clinicians should not routinely implant male slings in patients with severe stress incontinence. (Moderate Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 22

Clinicians may offer adjustable balloon devices to non-radiated patients with mild to severe stress urinary incontinence after prostate treatment. (Conditional Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 23

Clinicians should manage patients with stress urinary incontinence after treatment of benign prostatic hyperplasia the same as patients that have undergone radical prostatectomy. (Moderate Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 24

In patients with stress urinary incontinence after primary, adjuvant, or salvage radiotherapy who are seeking surgical management, clinicians should offer artificial urinary sphincter over male slings or adjustable balloons. (Moderate Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 25

In patients with incontinence after prostate treatment, clinicians should counsel patients that efficacy is low and cure is rare with urethral bulking agents. (Strong Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 26

Clinicians should consider other potential treatments for incontinence after prostate treatment as investigational, and patients should be counseled accordingly. (Expert Opinion)

Discussion


Complications After Surgery

Guideline Statement 27

Clinicians may counsel patients regarding risk factors for artificial urinary sphincter erosion. (Conditional Recommendation; Evidence Level: C)

Discussion


Guideline Statement 28

Clinicians should counsel patients that the artificial urinary sphincter will likely lose effectiveness over time, and reoperations are common. (Strong Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 29

In patients with persistent or recurrent urinary incontinence after artificial urinary sphincter or sling, clinicians should again perform history, physical examination, and/or other investigations to determine the cause of incontinence. (Clinical Principle)

Discussion


Guideline Statement 30

In patients with persistent or recurrent stress urinary incontinence after sling, clinicians should recommend an artificial urinary sphincter. (Moderate Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 31

In patients with persistent or recurrent stress urinary incontinence after artificial urinary sphincter, clinicians should discuss artificial urinary sphincter revision with the patient. (Strong Recommendation; Evidence Level: Grade B)

Discussion


Guideline Statement 32

In patients presenting with infection or erosion of an artificial urinary sphincter or sling, clinicians should perform explantation and reimplantation should be delayed. (Clinical Principle)

Discussion


Guideline Statement 33

After explanting an eroded device, clinicians may manage artificial urinary sphincter urethral cuff erosion intra-operatively with urethral catheter alone, in situ urethroplasty, or anastomotic urethroplasty. (Expert Opinion)

Discussion


Special Situations

Guideline Statement 34

Clinicians should discuss urinary diversion with patients who are unable to obtain long-term quality of life due to incontinence after prostate treatment. (Expert Opinion)

Discussion


Guideline Statement 35

In patients with bothersome incontinence during sexual activity, clinicians should offer treatment. (Moderate Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 36

In patients with stress urinary incontinence following urethral reconstructive surgery, clinicians may offer artificial urinary sphincter and counsel that complications rates are higher. (Conditional Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 37

In patients with incontinence after prostate treatment and erectile dysfunction (ED), clinicians may offer a concomitant or staged procedure. (Conditional Recommendation; Evidence Level: Grade C)

Discussion


Guideline Statement 38

In patients with symptomatic vesicourethral anastomotic stenosis (VUAS) or bladder neck contracture, clinicians should treat the patient prior to surgery for incontinence after prostate treatment. (Clinical Principle)

Discussion


FUTURE DIRECTIONS

In the future, refinements to therapies that create IPT will occur, decreasing incidence. The Panel expects continued enhancements in diagnostics and treatment options that will continue to improve patient continence and decrease the prevalence of IPT. Since most papers are single center experiences, the Panel expects and hopes to have increased multicenter research collaboration. Clinical trials of lifestyle interventions, medications, and surgeries will be needed to estimate therapeutic benefit while comparative effectiveness research can help determine which therapy to use and when. Patient reported outcome measures, which are very important in the treatment of QoL surgery have also become more prevalent; as such, the Panel expects these to also improve in use and quality, allowing clinicians to fully address patient concerns.

Refining which patient populations with SUI and BNC/VUAS will benefit from synchronous BNC/VUAS treatment and AUS placement rather than staged procedures will improve the QoL of many patients.

Newer treatments will encompass not only improvements in surgical products such as AUS and male slings, but will also include continued research into muscle injections, stem cells, and newer treatments for urgency and urge incontinence.

Developments regarding surgical products will likely include improvements to the current AUS, possibly improving the patient’s ability to use the pump. It may also include a more automated system controlled from an external device with no manual dexterity needed. With newer technologies, the Panel hopes to see automatic adjustments in cuff pressures or fluid volumes that would allow increased pressures improving continence with any increase in abdominal pressure. Dynamic pressuring could lead to less leakage and less wear on the urethra.

Male slings have continued to evolve from bone anchored slings to the current products on the market, including some that are adjustable. As clinicians learn more about etiology, continued development and improvements will increase efficacy of newer products.

The ATOMS® adjustable transobturator sling is currently approved for use in Europe and Canada; however, it is currently under review by the FDA. New evidence demonstrates that the ATOMS® adjustable sling is safe and effective for men with mild to severe SUI. However, patients with prior RT and prior surgery for urethral stricture had significantly worse continence rates, complication rates, and satisfaction rates compared to those who did not have these risk factors.2, 198

Some advances in the treatment of male SUI are expected to parallel those with female SUI. Regenerative medicine may shape future treatments attempting to restore normal function with either autologous muscle-derived cells or multipotent mesenchymal stem cells injected into the sphincter. While cell-based therapies have yet to produce long-term clinical improvement, hope exists that cellular regenerative therapies such as stem cells or low-intensity shockwave will lead to effective non-surgical therapies.

Tools & Resources

ABBREVIATIONS

95% CI95% confidence interval
AUAbbreviated urethroplasty
AUA American Urological Association
AUAERAmerican Urological Association Education and Research, Inc.
AUS Artificial urinary sphincter
BMIBody mass index
BNCBladder neck contracture
BODBoard of directors 
BPH Benign prostatic hyperplasia
EDErectile dysfunction
FDAU.S. Food and Drug Administration 
GURSSociety of Genitourinary Reconstructive Surgeons
HIFUHigh intensity focused ultrasound
IPPInflatable penile prosthesis
IPTIncontinence after prostate treatment
MRIMagnetic resonance imaging
OABOveractive bladder
OROdds ratio
PAPrimary urethral anastomosis
PFMEPelvic floor muscle exercise
PFMTPelvic floor muscle training
PGCPractice guidelines committee 
PVRPost-void residual
QoLQuality of life
RCTRandomized controlled trial
RPRadical prostatectomy
RTRadiation therapy 
SQCScience and Quality Council 
SUFUThe Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction
SUIStress urinary incontinence 
TCTranscorporal cuff
TURPTransurethral resection of the prostate
ULRUpdate literature review
UDSUrodynamic testing
VUASVesicourethral anastomotic stenosis

REFERENCES

  1. Henry GD, Graham SM, Cornell RJ et al: A multicenter study on the perineal versus penoscrotal approach for implantation of an artificial urinary sphincter: Cuff size and control of male stress urinary incontinence. J Urol 2009; 182: 2404
  2. Giammò A, Ammirati E, Tullio A et al: Implant of atoms® system for the treatment of postoperative male stress urinary incontinence: An italian multicentric study. Minerva Urol Nefrol 2020; 72: 770
  3. Nitti VW, Mourtzinos A and Brucker BM: Correlation of patient perception of pad use with objective degree of incontinence measured by pad test in men with post-prostatectomy incontinence: The sufu pad test study. J Urol 2014; 192: 836
  4. Suarez OA and McCammon KA: The artificial urinary sphincter in the management of incontinence. Urology 2016; 92: 14
  5. Lim B, Kim A, Song M et al: Comparing argus sling and artificial urinary sphincter in patients with moderate post-prostatectomy incontinence. J Exerc Rehabil 2014; 10: 337
  6. Methods guide for effectiveness and comparative effectiveness reviews. 2014; No. 10(14)-EHC063-EF
  7. BA HCaS: The delphi technique: Making sense of consensus. Practical Assessment, Research & Evaluation 2007; 1
  8. Barocas DA, Alvarez J, Resnick MJ et al: Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA 2017; 317: 1126
  9. Al Hussein Al Awamlh B, Wallis CJD, Penson DF et al: Functional outcomes after localized prostate cancer treatment. JAMA 2024; 331: 302
  10. Ávila M, Patel L, López S et al: Patient-reported outcomes after treatment for clinically localized prostate cancer: A systematic review and meta-analysis. Cancer Treat Rev 2018; 66: 23
  11. Crouzet S, Chapelon JY, Rouvière O et al: Whole-gland ablation of localized prostate cancer with high-intensity focused ultrasound: Oncologic outcomes and morbidity in 1002 patients. Eur Urol 2014; 65: 907
  12. Khan A, Khan AU, Siref L and Feloney M: Focal cryoablation of the prostate: Primary treatment in 163 patients with localized prostate cancer. Cureus 2023; 15: e37172
  13. Chen C, Chen Z, Wang K et al: Comparisons of health-related quality of life among surgery and radiotherapy for localized prostate cancer: A systematic review and meta-analysis. Oncotarget 2017; 8: 99057
  14. Jarosek SL, Virnig BA, Chu H and Elliott SP: Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both. Eur Urol 2015; 67: 273
  15. Novara G, Ficarra V, D'Elia C et al: Evaluating urinary continence and preoperative predictors of urinary continence after robot assisted laparoscopic radical prostatectomy. J Urol 2010; 184: 1028
  16. Kadono Y, Ueno S, Kadomoto S et al: Use of preoperative factors including urodynamic evaluations and nerve-sparing status for predicting urinary continence recovery after robot-assisted radical prostatectomy: Nerve-sparing technique contributes to the reduction of postprostatectomy incontinence. Neurourol Urodyn 2016; 35: 1034
  17. Jeong SJ, Kim HJ, Kim JH et al: Urinary continence after radical prostatectomy: Predictive factors of recovery after 1 year of surgery. Int J Urol 2012; 19: 1091
  18. Han K-s and Kim C-S: Effect of pubovesical complex reconstruction during robot-assisted laparoscopic prostatectomy on the recovery of urinary continence. J Laparoendosc Adv Surg Tech A 2015; 25: 814
  19. Kowalczyk KJ, Huang AC, Hevelone ND et al: Effect of minimizing tension during robotic-assisted laparoscopic radical prostatectomy on urinary function recovery. World J Urol 2013; 31: 515
  20. Sacco E, Prayer-Galetti T, Pinto F et al: Urinary incontinence after radical prostatectomy: Incidence by definition, risk factors and temporal trend in a large series with a long-term follow-up. BJU Int 2006; 97: 1234
  21. Matsushita K, Kent MT, Vickers AJ et al: Preoperative predictive model of recovery of urinary continence after radical prostatectomy. BJU Int 2015; 116: 577
  22. Mandel P, Preisser F, Graefen M et al: High chance of late recovery of urinary and erectile function beyond 12 months after radical prostatectomy. Eur Urol 2017; 71: 848
  23. Ficarra V, Crestani A, Rossanese M et al: Urethral-fixation technique improves early urinary continence recovery in patients who undergo retropubic radical prostatectomy. BJU Int 2017; 119: 245
  24. Choi SK, Park S and Ahn H: Randomized clinical trial of a bladder neck plication stitch during robot-assisted radical prostatectomy. Asian J Androl 2015; 17: 304
  25. Jo JK, Hong SK, Byun SS et al: Urinary continence after robot-assisted laparoscopic radical prostatectomy: The impact of intravesical prostatic protrusion. Yonsei Med J 2016; 57: 1145
  26. Abdollah F, Sun M, Suardi N et al: Prediction of functional outcomes after nerve-sparing radical prostatectomy: Results of conditional survival analyses. Eur Urol 2012; 62: 42
  27. Lee SW, Kang JH, Sung HH et al: Treatment outcomes of transurethral macroplastique injection for postprostatectomy incontinence. Korean J Urol 2014; 55: 182
  28. Palisaar JR, Roghmann F, Brock M et al: Predictors of short-term recovery of urinary continence after radical prostatectomy. World J Urol 2015; 33: 771
  29. Tewari AK, Ali A, Metgud S et al: Functional outcomes following robotic prostatectomy using athermal, traction free risk-stratified grades of nerve sparing. World J Urol 2013; 31: 471
  30. Jeong SJ, Yeon JS, Lee JK et al: Development and validation of nomograms to predict the recovery of urinary continence after radical prostatectomy: Comparisons between immediate, early, and late continence. World J Urol 2014; 32: 437
  31. Tienza A, Hevia M, Benito A et al: Mri factors to predict urinary incontinence after retropubic/laparoscopic radical prostatectomy. Int Urol Nephrol 2015; 47: 1343
  32. Tienza A, Robles JE, Hevia M et al: Prevalence analysis of urinary incontinence after radical prostatectomy and influential preoperative factors in a single institution. Aging Male 2017: 1
  33. Coughlin GD, Yaxley JW, Chambers SK et al: Robot-assisted laparoscopic prostatectomy versus open radical retropubic prostatectomy: 24-month outcomes from a randomised controlled study. Lancet Oncol 2018; 19: 1051
  34. Ilic D, Evans SM, Allan CA et al: Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer. Cochrane Database Syst Rev 2017; 9: CD009625
  35. Rocco B, Gregori A, Stener S et al: Posterior reconstruction of the rhabdosphincter allows a rapid recovery of continence after transperitoneal videolaparoscopic radical prostatectomy. Eur Urol 2007; 51: 996
  36. Kim IY, Hwang EA, Mmeje C et al: Impact of posterior urethral plate repair on continence following robot-assisted laparoscopic radical prostatectomy. Yonsei Med J 2010; 51: 427
  37. Zhao Z, Zhu H, Yu H et al: Comparison of intrafascial and non-intrafascial radical prostatectomy for low risk localized prostate cancer. Sci Rep 2017; 7: 17604
  38. Eastham JA, Kattan MW, Rogers E et al: Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996; 156: 1707
  39. Kadono Y, Nohara T, Kawaguchi S et al: Comparison of postoperative urinary continence and incontinence types between conventional and retzius-sparing robot-assisted radical prostatectomy. Neurourol Urodyn 2023; 42: 1411
  40. Egan J, Marhamati S, Carvalho FLF et al: Retzius-sparing robot-assisted radical prostatectomy leads to durable improvement in urinary function and quality of life versus standard robot-assisted radical prostatectomy without compromise on oncologic efficacy: Single-surgeon series and step-by-step guide. Eur Urol 2021; 79: 839
  41. Hatiboglu G, Teber D, Tichy D et al: Predictive factors for immediate continence after radical prostatectomy. World J Urol 2016; 34: 113
  42. Ko YH, Coelho RF, Chauhan S et al: Factors affecting return of continence 3 months after robot-assisted radical prostatectomy: Analysis from a large, prospective data by a single surgeon. J Urol 2012; 187: 190
  43. Lee DI, Wedmid A, Mendoza P et al: Bladder neck plication stitch: A novel technique during robot-assisted radical prostatectomy to improve recovery of urinary continence. J Endourol 2011; 25: 1873
  44. Mottet N, Boyer C, Chartier-Kastler E et al: Artificial urinary sphincter ams 800 for urinary incontinence after radical prostatectomy: The french experience. Urol Int 1998; 60 Suppl 2: 25
  45. Sammon J, Kim TK, Trinh QD et al: Anastomosis during robot-assisted radical prostatectomy: Randomized controlled trial comparing barbed and standard monofilament suture. Urology 2011; 78: 572
  46. Schlomm T, Heinzer H, Steuber T et al: Full functional-length urethral sphincter preservation during radical prostatectomy. Eur Urol 2011; 60: 320
  47. Kaye DR, Hyndman ME, Segal RL et al: Urinary outcomes are significantly affected by nerve sparing quality during radical prostatectomy. Urology 2013; 82: 1348
  48. Burkhard FC, Kessler TM, Fleischmann A et al: Nerve sparing open radical retropubic prostatectomy--does it have an impact on urinary continence? J Urol 2006; 176: 189
  49. Clavell-Hernandez J, Martin C and Wang R: Orgasmic dysfunction following radical prostatectomy:Review of current literature. Sex Med Rev 2017;
  50. Röscher P, Sathiram R, Milios JE and van Wyk JM: Mapping the prevalence and use of questionnaires to detect the neglected sexual side effects after prostate cancer treatment: A scoping review. Syst Rev 2022; 11: 2
  51. O'Neil BB, Presson A, Gannon J et al: Climacturia after definitive treatment of prostate cancer. J Urol 2014; 191: 159
  52. Choi JM, Nelson CJ, Stasi J and Mulhall JP: Orgasm associated incontinence (climacturia) following radical pelvic surgery: Rates of occurrence and predictors. J Urol 2007; 177: 2223
  53. Capogrosso P, Ventimiglia E, Serino A et al: Orgasmic dysfunction after robot-assisted versus open radical prostatectomy. Eur Urol 2016; 70: 223
  54. Mitchell SA, Jain RK, Laze J and Lepor H: Post-prostatectomy incontinence during sexual activity: A single center prevalence study. J Urol 2011; 186: 982
  55. Liss MA, Osann K, Canvasser N et al: Continence definition after radical prostatectomy using urinary quality of life: Evaluation of patient reported validated questionnaires. J Urol 2010; 183: 1464
  56. Manassero F, Traversi C, Ales V et al: Contribution of early intensive prolonged pelvic floor exercises on urinary continence recovery after bladder neck-sparing radical prostatectomy: Results of a prospective controlled randomized trial. Neurourol Urodyn 2007; 26: 985
  57. Patel MI, Yao J, Hirschhorn AD and Mungovan SF: Preoperative pelvic floor physiotherapy improves continence after radical retropubic prostatectomy. Int J Urol 2013; 20: 986
  58. Bales GT, Gerber GS, Minor TX et al: Effect of preoperative biofeedback/pelvic floor training on continence in men undergoing radical prostatectomy. Urology 2000; 56: 627
  59. Centemero A, Rigatti L, Giraudo D et al: Preoperative pelvic floor muscle exercise for early continence after radical prostatectomy: A randomised controlled study. Eur Urol 2010; 57: 1039
  60. Geraerts I, Van Poppel H, Devoogdt N et al: Pelvic floor muscle training for erectile dysfunction and climacturia 1 year after nerve sparing radical prostatectomy: A randomized controlled trial. Int J Impot Res 2016; 28: 9
  61. Parekh AR, Feng MI, Kirages D et al: The role of pelvic floor exercises on post-prostatectomy incontinence. J Urol 2003; 170: 130
  62. Burgio KL, Goode PS, Urban DA et al: Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: A randomized, controlled trial. J Urol 2006; 175: 196
  63. Tienforti D, Sacco E, Marangi F et al: Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: A randomized controlled trial. BJU Int 2012; 110: 1004
  64. Mock S, Leapman M, Stock RG et al: Risk of urinary incontinence following post-brachytherapy transurethral resection of the prostate and correlation with clinical and treatment parameters. J Urol 2013; 190: 1805
  65. Hu K and Wallner K: Urinary incontinence in patients who have a turp/tuip following prostate brachytherapy. Int J Radiat Oncol Biol Phys 1998; 40: 783
  66. Polland A, Vertosick EA, Sjoberg DD et al: Preoperative symptoms predict continence after post-radiation transurethral resection of prostate. Can J Urol 2017; 24: 8903
  67. Lerner SE, Blute ML and Zincke H: Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995; 154: 1103
  68. Stephenson AJ, Scardino PT, Bianco FJ, Jr. et al: Morbidity and functional outcomes of salvage radical prostatectomy for locally recurrent prostate cancer after radiation therapy. J Urol 2004; 172: 2239
  69. Gotto GT, Yunis LH, Vora K et al: Impact of prior prostate radiation on complications after radical prostatectomy. J Urol 2010; 184: 136
  70. Eandi JA, Link BA, Nelson RA et al: Robotic assisted laparoscopic salvage prostatectomy for radiation resistant prostate cancer. J Urol 2010; 183: 133
  71. Kaffenberger SD, Keegan KA, Bansal NK et al: Salvage robotic assisted laparoscopic radical prostatectomy: A single institution, 5-year experience. J Urol 2013; 189: 507
  72. Yuh B, Ruel N, Muldrew S et al: Complications and outcomes of salvage robot-assisted radical prostatectomy: A single-institution experience. BJU Int 2014; 113: 769
  73. Bates AS, Samavedi S, Kumar A et al: Salvage robot assisted radical prostatectomy: A propensity matched study of perioperative, oncological and functional outcomes. Eur J Surg Oncol 2015; 41: 1540
  74. Fernandez RA, Garcia-Hermoso A, Solera-Martinez M et al: Improvement of continence rate with pelvic floor muscle training post-prostatectomy: A meta-analysis of randomized controlled trials. Urol Int 2015; 94: 125
  75. Mariotti G, Sciarra A, Gentilucci A et al: Early recovery of urinary continence after radical prostatectomy using early pelvic floor electrical stimulation and biofeedback associated treatment. J Urol 2009; 181: 1788
  76. Marchiori D, Bertaccini A, Manferrari F et al: Pelvic floor rehabilitation for continence recovery after radical prostatectomy: Role of a personal training re-educational program. Anticancer Res 2010; 30: 553
  77. Van Kampen M, De Weerdt W, Van Poppel H et al: Effect of pelvic-floor re-education on duration and degree of incontinence after radical prostatectomy: A randomised controlled trial. Lancet 2000; 355: 98
  78. Overgard M, Angelsen A, Lydersen S and Morkved S: Does physiotherapist-guided pelvic floor muscle training reduce urinary incontinence after radical prostatectomy? A randomised controlled trial. Eur Urol 2008; 54: 438
  79. Anderson CA, Omar MI, Campbell SE et al: Conservative management for postprostatectomy urinary incontinence. Cochrane Database Syst Rev 2015; 1: Cd001843
  80. Baker H, Wellman S and Lavender V: Functional quality-of-life outcomes reported by men treated for localized prostate cancer: A systematic literature review. Oncol Nurs Forum 2016; 43: 199
  81. Donovan JL, Hamdy FC, Lane JA et al: Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med 2016; 375: 1425
  82. Stanford JL, Feng Z, Hamilton AS et al: Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: The prostate cancer outcomes study. JAMA 2000; 283: 354
  83. Seo HJ, Lee NR, Son SK et al: Comparison of robot-assisted radical prostatectomy and open radical prostatectomy outcomes: A systematic review and meta-analysis. Yonsei Med J 2016; 57: 1165
  84. De Carlo F, Celestino F, Verri C et al: Retropubic, laparoscopic, and robot-assisted radical prostatectomy: Surgical, oncological, and functional outcomes: A systematic review. Urol Int 2014; 93: 373
  85. Lardas M, Liew M, van den Bergh RC et al: Quality of life outcomes after primary treatment for clinically localised prostate cancer: A systematic review. Euro Urol 2017; 72: 869
  86. Choo MS, Choi WS, Cho SY et al: Impact of prostate volume on oncological and functional outcomes after radical prostatectomy: Robot-assisted laparoscopic versus open retropubic. Korean J Urol 2013; 54: 15
  87. Lucas MG, Bosch RJ, Burkhard FC et al: [european association of urology guidelines on assessment and nonsurgical management of urinary incontinence]. Actas Urol Esp 2013; 37: 199
  88. Habashy D, Losco G, Tse V et al: Mid-term outcomes of a male retro-urethral, transobturator synthetic sling for treatment of post-prostatectomy incontinence: Impact of radiotherapy and storage dysfunction. Neurourol Urodyn 2017; 36: 1147
  89. Zuckerman JM, Tisdale B and McCammon K: Advance male sling in irradiated patients with stress urinary incontinence. Can J Urol 2011; 18: 6013
  90. Fischer MC, Huckabay C and Nitti VW: The male perineal sling: Assessment and prediction of outcome. J Urol 2007; 177: 1414
  91. Castle EP, Andrews PE, Itano N et al: The male sling for post-prostatectomy incontinence: Mean followup of 18 months. J Urol 2005; 173: 1657
  92. Herschorn S, Bruschini H, Comiter C et al: Surgical treatment of stress incontinence in men. Neurourol Urodyn 2010; 29: 179
  93. Soto Gonzalez M, Da Cuna Carrera I, Lantaron Caeiro EM et al: Correlation between the 1-hour and 24-hour pad test in the assessment of male patients with post-prostatectomy urinary incontinence. Prog Urol 2018; 28: 536
  94. Hosier GW, Tennankore KK, Himmelman JG et al: Overactive bladder and storage lower urinary tract symptoms following radical prostatectomy. Urology 2016; 94: 193
  95. Thiruchelvam N, Cruz F, Kirby M et al: A review of detrusor overactivity and the overactive bladder after radical prostate cancer treatment. BJU Int 2015; 116: 853
  96. Kielb SJ and Clemens JQ: Comprehensive urodynamics evaluation of 146 men with incontinence after radical prostatectomy. Urology 2005; 66: 392
  97. Chung DE, Dillon B, Kurta J et al: Detrusor underactivity is prevalent after radical prostatectomy: Aurodynamic study including risk factors. Can Urol Assoc J 2013; 7: E33
  98. Gomha MA and Boone TB: Voiding patterns in patients with post-prostatectomy incontinence: Urodynamic and demographic analysis. J Urol 2003; 169: 1766
  99. Gormley EA, Lightner DJ, Burgio KL et al: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: Aua/sufu guideline. J Urol 2012; 188: 2455
  100. Gormley EA, Lightner DJ, Faraday M and Vasavada SP: Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: Aua/sufu guideline amendment. J Urol 2015; 193: 1572
  101. Ficazzola MA and Nitti VW: The etiology of post-radical prostatectomy incontinence and correlation of symptoms with urodynamic findings. J Urol 1998; 160: 1317
  102. Kobashi KC, Albo ME, Dmochowski RR et al: Surgical treatment of female stress urinary incontinence: Aua/sufu guideline. J Urol 2017; 198: 875
  103. Biardeau X, Aharony S, Campeau L and Corcos J: Artificial urinary sphincter: Report of the 2015 consensus conference. Neurourol Urodyn 2016; 35 Suppl 2: S8
  104. Newman DK, Guzzo T, Lee D and Jayadevappa R: An evidence-based strategy for the conservative management of the male patient with incontinence. Curr Opin Urol 2014; 24: 553
  105. Wilson L, Brown JS, Shin GP et al: Annual direct cost of urinary incontinence. Obstet Gynecol 2001; 98: 398
  106. Cooperberg MR, Master VA and Carroll PR: Health related quality of life significance of single pad urinary incontinence following radical prostatectomy. J Urol 2003; 170: 512
  107. Moore KN, Schieman S, Ackerman T et al: Assessing comfort, safety, and patient satisfaction with three commonly used penile compression devices. Urology 2004; 63: 150
  108. Kyle G: The use of urinary sheaths in male incontinence. Br J Nurs 2011; 20: 338
  109. Robinson J: Continence: Sizing and fitting a penile sheath. Br J Community Nurs 2006; 11: 420
  110. Barry MJ and Edgman-Levitan S: Shared decision making--pinnacle of patient-centered care. N Engl J Med 2012; 366: 780
  111. Greenfield S, Kaplan S and Ware JE, Jr.: Expanding patient involvement in care. Effects on patient outcomes. Ann Intern Med 1985; 102: 520
  112. Greenfield S, Kaplan SH, Ware JE, Jr. et al: Patients' participation in medical care: Effects on blood sugar control and quality of life in diabetes. J Gen Intern Med 1988; 3: 448
  113. Kaplan SH, Greenfield S and Ware JE, Jr.: Assessing the effects of physician-patient interactions on the outcomes of chronic disease. Med Care 1989; 27: S110
  114. Guadagnoli E and Ward P: Patient participation in decision-making. Soc Sci Med 1998; 47: 329
  115. Rehder P and Gozzi C: Transobturator sling suspension for male urinary incontinence including post-radical prostatectomy. Eur Urol 2007; 52: 860
  116. Nager CW, Brubaker L, Litman HJ et al: A randomized trial of urodynamic testing before stress-incontinence surgery. N Engl J Med 2012; 366: 1987
  117. Agarwal A, Rathi S, Patnaik P et al: Does preoperative urodynamic testing improve surgical outcomes in patients undergoing the transobturator tape procedure for stress urinary incontinence? A prospective randomized trial. Korean J Urol 2014; 55: 821
  118. Perez LM and Webster GD: Successful outcome of artificial urinary sphincters in men with post-prostatectomy urinary incontinence despite adverse implantation features. J Urol 1992; 148: 1166
  119. Trigo-Rocha F, Gomes CM and Pompeo ACL: Prospective study evaluating efficacy and safety of adjustable continence therapy (proact) for post radical prostatectomy urinary incontinence. Urology 2006; 67: 965
  120. Lai HH, Hsu EI and Boone TB: Urodynamic testing in evaluation of postradical prostatectomy incontinence before artificial urinary sphincter implantation. Urology 2009; 73: 1264
  121. Thiel DD, Young PR, Broderick GA et al: Do clinical or urodynamic parameters predict artificial urinary sphincter outcome in post-radical prostatectomy incontinence? Urology 2007; 69: 315
  122. Ballert KN and Nitti VW: Association between detrusor overactivity and postoperative outcomes in patients undergoing male bone anchored perineal sling. J Urol 2010; 183: 641
  123. Twiss C, Fleischmann N and Nitti VW: Correlation of abdominal leak point pressure with objective incontinence severity in men with post-radical prostatectomy stress incontinence. Neurourol Urodyn 2005; 24: 207
  124. Huckabay C, Twiss C, Berger A and Nitti VW: A urodynamics protocol to optimally assess men with post-prostatectomy incontinence. Neurourol Urodyn 2005; 24: 622
  125. Hoffman D, Vijay V, Peng M et al: Effect of radiation on male stress urinary incontinence and the role of urodynamic assessment. Urology 2018;
  126. Kaufman AM, Ritchey ML, Roberts AC et al: Decreased bladder compliance in patients with myelomeningocele treated with radiological observation. J Urol 1996; 156: 2031
  127. Ghoniem GM, Bloom DA, McGuire EJ and Stewart KL: Bladder compliance in meningomyelocele children. J Urol 1989; 141: 1404
  128. Moore KN, Valiquette L, Chetner MP et al: Return to continence after radical retropubic prostatectomy: A randomized trial of verbal and written instructions versus therapist-directed pelvic floor muscle therapy. Urology 2008; 72: 1280
  129. Wille S, Sobottka A, Heidenreich A and Hofmann R: Pelvic floor exercises, electrical stimulation and biofeedback after radical prostatectomy: Results of a prospective randomized trial. J Urol 2003; 170: 490
  130. Floratos DL, Sonke GS, Rapidou CA et al: Biofeedback vs verbal feedback as learning tools for pelvic muscle exercises in the early management of urinary incontinence after radical prostatectomy. BJU Int 2002; 89: 714
  131. Ribeiro LHS, Prota C, Gomes CM et al: Long-term effect of early postoperative pelvic floor biofeedback on continence in men undergoing radical prostatectomy: A prospective, randomized, controlled trial. J Urol 2010; 184: 1034
  132. Goode PS, Burgio KL, Johnson TM, 2nd et al: Behavioral therapy with or without biofeedback and pelvic floor electrical stimulation for persistent postprostatectomy incontinence: A randomized controlled trial. JAMA 2011; 305: 151
  133. Pannek J and Konig JE: Clinical usefulness of pelvic floor reeducation for men undergoing radical prostatectomy. Urol Int 2005; 74: 38
  134. Cornel EB, de Wit R and Witjes JA: Evaluation of early pelvic floor physiotherapy on the duration and degree of urinary incontinence after radical retropubic prostatectomy in a non-teaching hospital. World J Urol 2005; 23: 353
  135. Filocamo MT, Li Marzi V, Del Popolo G et al: Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. Eur Urol 2005; 48: 734
  136. Sacomani CAR, Zequi SdC, Costa WHd et al: Long-term results of the implantation of the ams 800 artificial sphincter for post-prostatectomy incontinence: A single-center experience. Int Braz J Urol 2017; 43: 07
  137. Walsh IK, Williams SG, Mahendra V et al: Artificial urinary sphincter implantation in the irradiated patient: Safety, efficacy and satisfaction. BJU Int 2002; 89: 364
  138. Gomha MA and Boone TB: Artificial urinary sphincter for post-prostatectomy incontinence in men who had prior radiotherapy: A risk and outcome analysis. J Urol 2002; 167: 591
  139. Litwiller SE, Kim KB, Fone PD et al: Post-prostatectomy incontinence and the artificial urinary sphincter: A long-term study of patient satisfaction and criteria for success. J Urol 1996; 156: 1975
  140. Trigo Rocha F, Gomes CM, Mitre AI et al: A prospective study evaluating the efficacy of the artificial sphincter ams 800 for the treatment of postradical prostatectomy urinary incontinence and the correlation between preoperative urodynamic and surgical outcomes. Urology 2008; 71: 85
  141. Guillaumier S, Solomon E, Jenks J et al: Radiotherapy is associated with reduced continence outcomes following implantation of the artificial urinary sphincter in men with post-radical prostatectomy incontinence. Urology Annals 2017; 9: 253
  142. Kuznetsov DD, Kim HL, Patel RV et al: Comparison of artificial urinary sphincter and collagen for the treatment of postprostatectomy incontinence. Urology 2000; 56: 600
  143. Gousse AE, Madjar S, Lambert MM and Fishman IJ: Artificial urinary sphincter for post-radical prostatectomy urinary incontinence: Long-term subjective results. J Urol 2001; 166: 1755
  144. Santos ACSDJ, Rodrigues LdO, Azevedo DC et al: Artificial urinary sphincter for urinary incontinence after radical prostatectomy: A historical cohort from 2004 to 2015. Int Braz J Urol 2017; 43: 150
  145. Lai HH, Hsu EI, Teh BS et al: 13 years of experience with artificial urinary sphincter implantation at baylor college of medicine. J Urol 2007; 177: 1021
  146. Scott FB, Bradley WE and Timm GW: Treatment of urinary incontinence by an implantable prosthetic urinary sphincter. 1974. J Urol 2002; 167: 1125
  147. Kretschmer A, Husch T, Thomsen F et al: Complications and short-term explantation rate following artificial urinary sphincter implantation: Results from a large middle european multi-institutional case series. Urol Int 2016; 97: 205
  148. Ahyai SA, Ludwig TA, Dahlem R et al: Outcomes of single- vs double-cuff artificial urinary sphincter insertion in low- and high-risk profile male patients with severe stress urinary incontinence. BJU Int 2016; 118: 625
  149. O'Connor RC, Lyon MB, Guralnick ML and Bales GT: Long-term follow-up of single versus double cuff artificial urinary sphincter insertion for the treatment of severe postprostatectomy stress urinary incontinence. Urology 2008; 71: 90
  150. Wolf JS, Jr., Bennett CJ, Dmochowski RR et al: Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol 2008; 179: 1379
  151. Le Portz B, Haillot O, Brouziyne M and Saussine C: Surgimesh m-sling((r)) transobturator and prepubic four-arm urethral sling for post-prostatectomy stress urinary incontinence: Clinical prospective assessment at 24 months. BJU Int 2016; 117: 966
  152. Soljanik I, Becker AJ, Stief CG et al: Repeat retrourethral transobturator sling in the management of recurrent postprostatectomy stress urinary incontinence after failed first male sling. Eur Urol 2010; 58: 767
  153. Carmel M, Hage B, Hanna S et al: Long-term efficacy of the bone-anchored male sling for moderate and severe stress urinary incontinence. BJU Int 2010; 106: 1012
  154. Xu YM, Zhang XR, Sa YL et al: Bulbourethral composite suspension for treatment of male-acquired urinary incontinence. Eur Urol 2007; 51: 1709
  155. Romano SV, Metrebian SE, Vaz F et al: An adjustable male sling for treating urinary incontinence after prostatectomy: A phase iii multicentre trial. BJU Int 2006; 97: 533
  156. Ullrich NFE and Comiter CV: The male sling for stress urinary incontinence: Urodynamic and subjective assessment. J Urol 2004; 172: 204
  157. Comiter CV: The male sling for stress urinary incontinence: A prospective study. J Urol 2002; 167: 597
  158. John H: Bulbourethral composite suspension:: A new operative technique for post-prostatectomy incontinence. J Urol 2004; 171: 1866
  159. Wadie BS: A novel technique of bulbourethral sling for post-prostatectomy incontinence. Scand J Urol Nephrol 2007; 41: 398
  160. Rehder P, Haab F, Cornu JN et al: Treatment of postprostatectomy male urinary incontinence with the transobturator retroluminal repositioning sling suspension: 3-year follow-up. Eur Urol 2012; 62: 140
  161. Zuckerman JM, Henderson K and McCammon K: Transobturator male sling: Is there a learning curve? Can J Urol 2013; 20: 6768
  162. Stern JA, Clemens JQ, Tiplitsky SI et al: Long-term results of the bulbourethral sling procedure. J Urol 2005; 173: 1654
  163. Hubner WA, Gallistl H, Rutkowski M and Huber ER: Adjustable bulbourethral male sling: Experience after 101 cases of moderate-to-severe male stress urinary incontinence. BJU Int 2011; 107: 777
  164. Madjar S, Jacoby K, Giberti C et al: Bone anchored sling for the treatment of post-prostatectomy incontinence. J Urol 2001; 165: 72
  165. Giberti C, Gallo F, Schenone M et al: The bone anchor suburethral synthetic sling for iatrogenic male incontinence: Critical evaluation at a mean 3-year followup. J Urol 2009; 181: 2204
  166. Bauer RM, Mayer ME, May F et al: Complications of the advance transobturator male sling in the treatment of male stress urinary incontinence. Urology 2010; 75: 1494
  167. Comiter C: Surgery for postprostatectomy incontinence: Which procedure for which patient? Nat Rev Urol 2015; 12: 91
  168. Cornu JN, Sebe P, Ciofu C et al: The advance transobturator male sling for postprostatectomy incontinence: Clinical results of a prospective evaluation after a minimum follow-up of 6 months. Eur Urol 2009; 56: 923
  169. Bauer RM, Soljanik I, Fullhase C et al: Mid-term results for the retroluminar transobturator sling suspension for stress urinary incontinence after prostatectomy. BJU Int 2011; 108: 94
  170. Nash S, Aboseif S, Gilling P et al: Four-year follow-up on 68 patients with a new post-operatively adjustable long-term implant for post-prostatectomy stress incontinence: Proact™. Neurourol Urodyn 2019; 38: 248
  171. Angulo JC, Schönburg S, Giammò A et al: Systematic review and meta-analysis comparing adjustable transobturator male system (atoms) and adjustable continence therapy (proact) for male stress incontinence. PLoS One 2019; 14: e0225762
  172. Larson T, Jhaveri H and Yeung LL: Adjustable continence therapy (proact) for the treatment of male stress urinary incontinence: A systematic review and meta-analysis. Neurourol Urodyn 2019; 38: 2051
  173. Tricard T, Song QX, Munier P et al: Adjustable continence therapy (proact) for the treatment of male stress urinary incontinence post-prostatectomy: A systematic review and meta-analysis (2023 update). World J Urol 2023; 41: 1793
  174. Noordhoff TC, Scheepe JR and Blok BFM: Outcome and complications of adjustable continence therapy (proact™) after radical prostatectomy: 10 years' experience in 143 patients. Neurourol Urodyn 2018; 37: 1419
  175. Finazzi Agrò E, Gregori A, Bianchi D et al: Efficacy and safety of adjustable balloons (proact™) to treat male stress urinary incontinence after prostate surgery: Medium and long-term follow-up data of a national multicentric retrospective study. Neurourol Urodyn 2019; 38: 1979
  176. Ricard H, Léon G, Branchereau J et al: Adjustable continence balloons in postprostatectomy incontinence: Outcomes and complications. Neurourol Urodyn 2022; 41: 1414
  177. Nestler S, Thomas C, Neisius A et al: Long-term results of proact primary and repeat implantation for treatment of stress urinary incontinence in men. World J Urol 2019; 37: 1173
  178. Hubner WA and Schlarp OM: Adjustable continence therapy (proact): Evolution of the surgical technique and comparison of the original 50 patients with the most recent 50 patients at a single centre. Eur Urol 2007; 52: 680
  179. Silva LA, Andriolo RB, Atallah AN and da Silva EM: Surgery for stress urinary incontinence due to presumed sphincter deficiency after prostate surgery. Cochrane Database Syst Rev 2014: Cd008306
  180. Gratzke C, Bachmann A, Descazeaud A et al: Eau guidelines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2015; 67: 1099
  181. Gundian JC, Barrett DM and Parulkar BG: Mayo clinic experience with the as800 artificial urinary sphincter for urinary incontinence after transurethral resection of prostate or open prostatectomy. Urology 1993; 41: 318
  182. Kretschmer A, Buchner A, Leitl B et al: Long-term outcome of the retrourethral transobturator male sling after transurethral resection of the prostate. Int Neurourol J 2016; 20: 335
  183. Hogewoning CRC, Meij LAM, Pelger RCM et al: Sling surgery for the treatment of urinary incontinence after transurethral resection of the prostate: New data on the virtue male sling and an evaluation of literature. Urology 2017; 100: 187
  184. Bastian PJ, Boorjian SA, Bossi A et al: High-risk prostate cancer: From definition to contemporary management. Eur Urol 2012; 61: 1096
  185. Hudak SJ and Morey AF: Impact of 3.5 cm artificial urinary sphincter cuff on primary and revision surgery for male stress urinary incontinence. J Urol 2011; 186: 1962
  186. Manunta A, Guille F, Patard JJ and Lobel B: Artificial sphincter insertion after radiotherapy: Is it worthwhile? BJU Int 2000; 85: 490
  187. Ravier E, Fassi-Fehri H, Crouzet S et al: Complications after artificial urinary sphincter implantation in patients with or without prior radiotherapy. BJU Int 2015; 115: 300
  188. Sathianathen NJ, McGuigan SM and Moon DA: Outcomes of artificial urinary sphincter implantation in the irradiated patient. BJU Int 2014; 113: 636
  189. Bates AS, Martin RM and Terry TR: Complications following artificial urinary sphincter placement after radical prostatectomy and radiotherapy: A meta-analysis. BJU Int 2015; 116: 623
  190. Hird AE and Radomski SB: Artificial urinary sphincter erosion after radical prostatectomy in patients treated with and without radiation. Can Urol Assoc J 2015; 9: E354
  191. Wright HC, McGeagh K, Richter LA et al: Transobturator sling for post-prostatectomy incontinence: Radiation's effect on efficacy/satisfaction. Can J Urol 2017; 24: 8998
  192. Dosanjh A, Baldwin S, Mytton J et al: A national study of artificial urinary sphincter and male sling implantation after radical prostatectomy in england. BJU Int 2020; 125: 467
  193. Angulo JC, Ruiz S, Lozano M et al: Systematic review and meta-analysis comparing adjustable transobturator male system (atoms) and male readjustment mechanical external (remeex) system for post-prostatectomy incontinence. World J Urol 2021; 39: 1083
  194. Altan M, Asi T, Bilen CY and Ergen A: Adjustable perineal male sling for the treatment of urinary incontinence: Long-term results. Urology 2017; 106: 216
  195. Friedl A, Mühlstädt S, Zachoval R et al: Long-term outcome of the adjustable transobturator male system (atoms): Results of a european multicentre study. BJU Int 2017; 119: 785
  196. Giammò A, Ammirati E, Tullio A et al: Implant of atoms® system for the treatment of postoperative male stress urinary incontinence: Results of a single centre. Int Braz J Urol 2019; 45: 127
  197. Redmond EJ, Nadeau G, Tu LM et al: Multicentered assessment of clinical outcomes and factors associated with failure of the adjustable transobturator male system (atoms). Urology 2021; 148: 280
  198. Mühlstädt S, Angulo JC, Mohammed N et al: Complications of the urinary incontinence system atoms: Description of risk factors and how to prevent these pitfalls. World J Urol 2020; 38: 1795
  199. Li Marzi V, Morselli S, Fusco F et al: Advance xp® male sling can be an effective and safe treatment for post-prostatectomy stress urinary incontinence also in patients with prior history of external beam radiation therapy: A multicentric experience. Surg Innov 2021; 28: 723
  200. Poon SA, Silberstein JL, Savage C et al: Surgical practice patterns for male urinary incontinence: Analysis of case logs from certifying american urologists. J Urol 2012; 188: 205
  201. Elsergany R, Elgamasy AN and Ghoniem GM: Transurethral collagen injection for female stress incontinence. Int Urogynecol J Pelvic Floor Dysfunct 1998; 9: 13
  202. Cespedes RD, Leng WW and McGuire EJ: Collagen injection therapy for postprostatectomy incontinence. Urology 1999; 54: 597
  203. Kim PH, Pinheiro LC, Atoria CL et al: Trends in the use of incontinence procedures after radical prostatectomy: A population based analysis. J Urol 2013; 189: 602
  204. Westney OL, Bevan-Thomas R, Palmer JL et al: Transurethral collagen injections for male intrinsic sphincter deficiency: The university of texas-houston experience. J Urol 2005; 174: 994
  205. Secin FP, Martinez-Salamanca JI and Eilber KS: [limited efficacy of permanent injectable agents in the treatment of stress urinary incontinence after radical prostatectomy]. Arch Esp Urol 2005; 58: 431
  206. Kylmala T, Tainio H, Raitanen M and Tammela TL: Treatment of postoperative male urinary incontinence using transurethral macroplastique injections. J Endourol 2003; 17: 113
  207. Imamoglu MA, Tuygun C, Bakirtas H et al: The comparison of artificial urinary sphincter implantation and endourethral macroplastique injection for the treatment of postprostatectomy incontinence. Eur Urol 2005; 47: 209
  208. Yokoyama T, Nishiguchi J, Watanabe T et al: Comparative study of effects of extracorporeal magnetic innervation versus electrical stimulation for urinary incontinence after radical prostatectomy. Urology 2004; 63: 264
  209. Fode M and Sonksen J: Penile vibratory stimulation in the treatment of post-prostatectomy incontinence: A randomized pilot study. Neurourol Urodyn 2015; 34: 117
  210. Guyatt G, Oxman AD, Akl EA et al: Grade guidelines: 1. Introduction-grade evidence profiles and summary of findings tables. J Clin Epidemiol 2011; 64: 383
  211. Raj GV, Peterson AC and Webster GD: Outcomes following erosions of the artificial urinary sphincter. J Urol 2006; 175: 2186
  212. Kaufman MR, Milam DF, Johnsen NV et al: Prior radiation therapy decreases time to idiopathic erosion of artificial urinary sphincter: A multi-institutional analysis. J Urol 2018; 199: 1037
  213. Huang MM, Huffman P, Dani H et al: Association between previous pelvic radiation and all-cause and cause-specific failure of replacement artificial urinary sphincters. J Urol 2022; 207: 1268
  214. Brant WO, Erickson BA, Elliott SP et al: Risk factors for erosion of artificial urinary sphincters: A multicenter prospective study. Urology 2014; 84: 934
  215. Sayedahmed K, Olianas R, Kaftan B et al: Impact of previous urethroplasty on the outcome after artificial urinary sphincter implantation: A prospective evaluation. World J Urol 2020; 38: 183
  216. Mann RA, Kasabwala K, Buckley JC et al: The "fragile" urethra as a predictor of early artificial urinary sphincter erosion. Urology 2022; 169: 233
  217. McGeady JB, McAninch JW, Truesdale MD et al: Artificial urinary sphincter placement in compromised urethras and survival: A comparison of virgin, radiated and reoperative cases. J Urol 2014; 192: 1756
  218. McKibben MJ, Shakir N, Fuchs JS et al: Erosion rates of 3.5-cm artificial urinary sphincter cuffs are similar to larger cuffs. BJU Int 2019; 123: 335
  219. Simhan J, Morey AF, Singla N et al: 3.5 cm artificial urinary sphincter cuff erosion occurs predominantly in irradiated patients. J Urol 2015; 193: 593
  220. Queissert F, Huesch T, Kretschmer A et al: Artificial urinary sphincter cuff size predicts outcome in male patients treated for stress incontinence: Results of a large central european multicenter cohort study. Int Neurourol J 2019; 23: 219
  221. Wilson S, Delk J, 2nd, Henry GD and Siegel AL: New surgical technique for sphincter urinary control system using upper transverse scrotal incision. J Urol 2003; 169: 261
  222. Guralnick ML, Miller E, Toh KL and Webster GD: Transcorporal artificial urinary sphincter cuff placement in cases requiring revision for erosion and urethral atrophy. J Urol 2002; 167: 2075
  223. Moser DC, Kaufman MR, Milam DF et al: Impact of radiation and transcorporeal artificial sphincter placement in patients with prior urethral cuff erosion: Results from a retrospective multicenter analysis. J Urol 2018; 200: 1338
  224. Linder BJ, de Cogain M and Elliott DS: Long-term device outcomes of artificial urinary sphincter reimplantation following prior explantation for erosion or infection. J Urol 2014; 191: 734
  225. Raj GV, Peterson AC, Toh KL and Webster GD: Outcomes following revisions and secondary implantation of the artificial urinary sphincter. J Urol 2005; 173: 1242
  226. Kowalczyk JJ, Nelson R and Mulcahy JJ: Successful reinsertion of the artificial urinary sphincter after removal for erosion or infection. Urology 1996; 48: 906
  227. Motley RC and Barrett DM: Artificial urinary sphincter cuff erosion. Experience with reimplantation in 38 patients. Urology 1990; 35: 215
  228. Lai HH and Boone TB: Complex artificial urinary sphincter revision and reimplantation cases--how do they fare compared to virgin cases? J Urol 2012; 187: 951
  229. Viers BR, Linder BJ, Rivera ME et al: Long-term quality of life and functional outcomes among primary and secondary artificial urinary sphincter implantations in men with stress urinary incontinence. J Urol 2016; 196: 838
  230. Brucker BM, Demirtas A, Fong E et al: Artificial urinary sphincter revision: The role of ultrasound. Urology 2013; 82: 1424
  231. Bauer RM, Mayer ME, Gratzke C et al: Prospective evaluation of the functional sling suspension for male postprostatectomy stress urinary incontinence: Results after 1 year. Euro Urol 2009; 56: 928
  232. Ajay D, Zhang HJ, Gupta S et al: The artificial urinary sphincter is superior to a secondary transobturator male sling in cases of a primary sling failure. J Urol 2015; 194: 1038
  233. Fisher MB, Aggarwal N, Vuruskan H and Singla AK: Efficacy of artificial urinary sphincter implantation after failed bone-anchored male sling for postprostatectomy incontinence. Urology 2007; 70: 942
  234. Lentz AC, Peterson AC and Webster GD: Outcomes following artificial sphincter implantation after prior unsuccessful male sling. J Urol 2012; 187: 2149
  235. Singla N, Siegel JA, Simhan J et al: Does pressure regulating balloon location make a difference in functional outcomes of artificial urinary sphincter? J Urol 2015; 194: 202
  236. Maximilien B, Aublea A, Gillibert A et al: Urethral pressure controlled balloon refilling or balloon change for artificial sphincter secondary procedure? Prog Urol 2018; 28: 209
  237. Mock S, Dmochowski RR, Brown ET et al: The impact of urethral risk factors on transcorporeal artificial urinary sphincter erosion rates and device survival. J Urol 2015; 194: 1692
  238. Bryan DE, Mulcahy JJ and Simmons GR: Salvage procedure for infected noneroded artificial urinary sphincters. J Urol 2002; 168: 2464
  239. Rozanski AT, Tausch TJ, Ramirez D et al: Immediate urethral repair during explantation prevents stricture formation after artificial urinary sphincter cuff erosion. J Urol 2014; 192: 442
  240. Aaronson DS, Elliott SP and McAninch JW: Transcorporal artificial urinary sphincter placement for incontinence in high-risk patients after treatment of prostate cancer. Urology 2008; 72: 825
  241. Trost L and Elliott D: Small intestinal submucosa urethral wrap at the time of artificial urinary sphincter placement as a salvage treatment option for patients with persistent/recurrent incontinence following multiple prior sphincter failures and erosions. Urology 2012; 79: 933
  242. Margreiter M, Farr A, Sharma V et al: Urethral buttressing in patients undergoing artificial urinary sphincter surgery. J Urol 2013; 189: 1777
  243. Chertack N, Chaparala H, Angermeier KW et al: Foley or fix: A comparative analysis of reparative procedures at the time of explantation of artificial urinary sphincter for cuff erosion. Urology 2016; 90: 173
  244. Chertack NA, Caldwell KM, Joice GA et al: Long-term lower urinary tract sequelae following aus cuff erosion. Neurourol Urodyn 2022; 41: 229
  245. Salonia A, Burnett AL, Graefen M et al: Prevention and management of postprostatectomy sexual dysfunctions part 2: Recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol 2012; 62: 273
  246. Mehta A, Deveci S and Mulhall JP: Efficacy of a penile variable tension loop for improving climacturia after radical prostatectomy. BJU Int 2013; 111: 500
  247. Jain R, Mitchell S, Laze J and Lepor H: The effect of surgical intervention for stress urinary incontinence (ui) on post-prostatectomy ui during sexual activity. BJU Int 2012; 109: 1208
  248. Christine B BA: Climacturia: An under-addressed sequela of radical prostatectomy, but treatment is only a sling away. J Urol 2016; 195: e636
  249. Yafi FA, Andrianne R, Brady J et al: "Andrianne mini-jupette" graft at the time of inflatable penile prosthesis placement for the management of post-prostatectomy climacturia and minimal urinary incontinence. J Sex Med 2018; 15: S146
  250. Hampson LA, McAninch JW and Breyer BN: Male urethral strictures and their management. Nat Rev Urol 2014; 11: 43
  251. Keihani S, Chandrapal JC, Peterson AC et al: Outcomes of urethroplasty to treat urethral strictures arising from artificial urinary sphincter erosions and rates of subsequent device replacement. Urology 2017; 107: 239
  252. Kumar R and Nehra A: Dual implantation of penile and sphincter implants in the post-prostatectomy patient. Curr Urol Rep 2007; 8: 477
  253. Zafirakis H, Wang R and Westney OL: Combination therapy for male erectile dysfunction and urinary incontinence. Asian J Androl 2008; 10: 149
  254. Segal RL, Cabrini MR, Harris ED et al: Combined inflatable penile prosthesis-artificial urinary sphincter implantation: No increased risk of adverse events compared to single or staged device implantation. J Urol 2013; 190: 2183
  255. Mancini JG, Kizer WS, Jones LA et al: Patient satisfaction after dual implantation of inflatable penile and artificial urinary sphincter prostheses. Urology 2008; 71: 893
  256. Patel N, Golan R, Halpern JA et al: A contemporary analysis of dual inflatable penile prosthesis and artificial urinary sphincter outcomes. J Urol 2019; 201: 141
  257. Weissbart SJ, Chughtai B, Elterman D and Sandhu JS: Management of anastomotic stricture after artificial urinary sphincter placement in patients who underwent salvage prostatectomy. Urology 2013; 82: 476